

Europe Biologics Market Forecast to 2031 - Regional Analysis - by Product (Monoclonal Antibodies, Vaccine, Recombinant Hormones/Proteins, Cell and Gene Therapy, and Others), Application (Cancer, Infectious Diseases, Autoimmune Diseases, and Others), Source (Mammalian and Microbial), and Manufacturing (Outsourced and In-house)

<https://marketpublishers.com/r/E01576F8CC41EN.html>

Date: April 2025

Pages: 162

Price: US\$ 3,450.00 (Single User License)

ID: E01576F8CC41EN

Abstracts

The Europe biologics market was valued at US\$ 1,15,057.6 million in 2023 and is expected to reach US\$ 4,15,468.4 million by 2031; it is estimated to register a CAGR of 17.4% from 2023 to 2031.

Preference for Outsourcing Manufacturing Operations Drives Europe Biologics Market

Biologics manufacturing is a complex process whose success depends on the proper execution and monitoring of all operations. The manufacturing facilities need trained personnel with technical knowledge of bioprocessing and process engineering. Managing the attempts to reach the first clinical trial using a manual and open manufacturing method and then building a more commercially suitable process can be tricky for an experienced team. Thus, manufacturers choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization operations. CDMOs provide product development, clinical trial support, manufacturing, and commercialization services to biologics companies on a contract basis. Partnering with CDMO enables scalability and access to technical expertise without overhead costs, along with higher speed to market and greater cost efficiencies for biologics manufacturers. In April 2022, ThermoGenesis established its own CDMO facility in California, US, to provide CDMO services to cell

and gene therapy manufacturers. Using its expertise, the company focuses on manufacturing chimeric antigen receptor-T cell (CAR-T cell), T-cell receptor (TCR), tumor-infiltrating leukocyte (TIL), natural killer cell (NK), iPSC, and mesenchymal stem cell (MSC). Outsourcing biologics manufacturing to CDMOs proves cost-effective for manufacturers. Additionally, they gain access to the technologically advanced infrastructure and expertise of CDMOs. CDMOs employ proper, mapped processes for manufacturing biologics. Thus, the surging preference for outsourcing biologics manufacturing operations to CDMOs fuels the biologics market growth.

Europe Biologics Market Overview

The biologics market in Europe is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe holds the second-largest market share, which can be attributed to the increasing cancer burden and technological advancements in cancer diagnostics to aid in early detection. The growing use of monoclonal antibodies in various R&D applications, cancer therapies, and immunological disorders is also contributing to the biologics market progress in Europe. Germany invests significantly in healthcare research and infrastructure among all countries in the European Union (EU). According to Eurostat, the healthcare expenditure in Germany accounted for US\$ 394.9 million in 2015, which was one of the highest among the relative countries in the region. According to OECD Health Statistics 2015, health spending in Germany is growing faster than the actual OECD-predicted average; this can be associated with the higher capital investments made to support the development, research, and manufacturing of pharmaceuticals. Thus, the robust financial backing to the healthcare sector bolsters the biologics market in Germany.

Europe Biologics Market Revenue and Forecast to 2031 (US\$ Million)

Europe Biologics Market Segmentation

The Europe biologics market is categorized into product, application, source, manufacturing, and country.

Based on product, the Europe biologics market is segmented into monoclonal antibodies, vaccine, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.

In terms of application, the Europe biologics market is categorized into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the

largest market share in 2023.

By source, the Europe biologics market is bifurcated into mammalian and microbial. The mammalian segment held a larger market share in 2023.

Based on manufacturing, the Europe biologics market is bifurcated into outsourced and in-house. The outsourced segment held a larger market share in 2023.

In terms of country, the Europe biologics market is segmented into Germany, the UK, Italy, France, Spain, and the Rest of Europe. Germany dominated the Europe biologics market share in 2023.

AbbVie Inc; Pfizer Inc; Samsung Biologics Co Ltd; ADMA Biologics, Inc.; Wuxi Biologics Inc; Catalent Inc; AGC Biologics AS; AstraZeneca Plc; Amgen Inc; Nitto Avecia; and Quality Assistance s.a. are some of the leading companies operating in the Europe biologics market.

Reason to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe biologics market.

Highlights key business priorities to assist companies to realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the Europe biologics market, thereby allowing players across the value chain to develop effective long-term strategies.

Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe biologics market, as well as those hindering it.

Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

The List of Companies - Europe Biologics Market

AbbVie Inc

Pfizer Inc

Samsung Biologics Co Ltd

ADMA Biologics, Inc.

Wuxi Biologics Inc

Catalent Inc

AGC Biologics AS

AstraZeneca Plc

Amgen Inc

Nitto Avecia

Quality Assistance s.a.

Contents

1. INTRODUCTION

- 1.1 Report Guidance
- 1.2 Market Segmentation

2. EXECUTIVE SUMMARY

- 2.1 Key Insights
- 2.2 Market Attractiveness

3. RESEARCH METHODOLOGY

- 3.1 Secondary Research
- 3.2 Primary Research
 - 3.2.1 Hypothesis formulation:
 - 3.2.2 Macroeconomic factor analysis:
 - 3.2.3 Developing base number:
 - 3.2.4 Data Triangulation:
 - 3.2.5 Country-level data:

4. EUROPE BIOLOGICS MARKET - KEY MARKET DYNAMICS

- 4.1 Market Drivers
 - 4.1.1 Increasing Prevalence of Chronic Diseases
 - 4.1.2 Preference for Outsourcing Manufacturing Operations
- 4.2 Market Restraints
 - 4.2.1 High Cost of Biologics
- 4.3 Market Opportunities
 - 4.3.1 Gene and Cell Therapy Advancements in Biologics
- 4.4 Future Trends
 - 4.4.1 Strategic Initiatives by Companies
- 4.5 Impact of Drivers and Restraints:

5. BIOLOGICS MARKET - EUROPE ANALYSIS

- 5.1 Europe Biologics Market Revenue (US\$ Million), 2021-2031
- 5.2 Europe Biologics Market Forecast Analysis

6. EUROPE BIOLOGICS MARKET ANALYSIS - BY PRODUCT

6.1 Monoclonal Antibodies

6.1.1 Overview

6.1.2 Monoclonal Antibodies: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

6.2 Vaccine

6.2.1 Overview

6.2.2 Vaccine: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

6.3 Recombinant Hormones/Proteins

6.3.1 Overview

6.3.2 Recombinant Hormones/Proteins: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

6.4 Cell and Gene Therapy

6.4.1 Overview

6.4.2 Cell and Gene Therapy: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

6.5 Others

6.5.1 Overview

6.5.2 Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

7. EUROPE BIOLOGICS MARKET ANALYSIS - BY APPLICATION

7.1 Cancer

7.1.1 Overview

7.1.2 Cancer: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

7.2 Infectious Diseases

7.2.1 Overview

7.2.2 Infectious Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

7.3 Autoimmune Diseases

7.3.1 Overview

7.3.2 Autoimmune Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

7.4 Others

7.4.1 Overview

7.4.2 Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

8. EUROPE BIOLOGICS MARKET ANALYSIS - BY SOURCE

8.1 Mammalian

8.1.1 Overview

8.1.2 Mammalian: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

8.2 Microbial

8.2.1 Overview

8.2.2 Microbial: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

9. EUROPE BIOLOGICS MARKET ANALYSIS - BY MANUFACTURING

9.1 Outsourced

9.1.1 Overview

9.1.2 Outsourced: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

9.2 In-house

9.2.1 Overview

9.2.2 In-house: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

10. EUROPE BIOLOGICS MARKET - COUNTRY ANALYSIS

10.1 Europe

10.1.1 Europe Biologics Market - Revenue and Forecast Analysis - by Country

10.1.1.1 Europe Biologics Market - Revenue and Forecast Analysis - by Country

10.1.1.2 Germany: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

10.1.1.2.1 Germany: Europe Biologics Market Share - by Product

10.1.1.2.2 Germany: Europe Biologics Market Share - by Application

10.1.1.2.3 Germany: Europe Biologics Market Share - by Source

10.1.1.2.4 Germany: Europe Biologics Market Share - by Manufacturing

10.1.1.3 United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

- 10.1.1.3.1 United Kingdom: Europe Biologics Market Share - by Product
- 10.1.1.3.2 United Kingdom: Europe Biologics Market Share - by Application
- 10.1.1.3.3 United Kingdom: Europe Biologics Market Share - by Source
- 10.1.1.3.4 United Kingdom: Europe Biologics Market Share - by Manufacturing
- 10.1.1.4 Italy: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)
 - 10.1.1.4.1 Italy: Europe Biologics Market Share - by Product
 - 10.1.1.4.2 Italy: Europe Biologics Market Share - by Application
 - 10.1.1.4.3 Italy: Europe Biologics Market Share - by Source
 - 10.1.1.4.4 Italy: Europe Biologics Market Share - by Manufacturing
- 10.1.1.5 France: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)
 - 10.1.1.5.1 France: Europe Biologics Market Share - by Product
 - 10.1.1.5.2 France: Europe Biologics Market Share - by Application
 - 10.1.1.5.3 France: Europe Biologics Market Share - by Source
 - 10.1.1.5.4 France: Europe Biologics Market Share - by Manufacturing
- 10.1.1.6 Spain: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)
 - 10.1.1.6.1 Spain: Europe Biologics Market Share - by Product
 - 10.1.1.6.2 Spain: Europe Biologics Market Share - by Application
 - 10.1.1.6.3 Spain: Europe Biologics Market Share - by Source
 - 10.1.1.6.4 Spain: Europe Biologics Market Share - by Manufacturing
- 10.1.1.7 Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)
 - 10.1.1.7.1 Rest of Europe: Europe Biologics Market Share - by Product
 - 10.1.1.7.2 Rest of Europe: Europe Biologics Market Share - by Application
 - 10.1.1.7.3 Rest of Europe: Europe Biologics Market Share - by Source
 - 10.1.1.7.4 Rest of Europe: Europe Biologics Market Share - by Manufacturing

11. INDUSTRY LANDSCAPE

- 11.1 Overview
- 11.2 Market Initiative
- 11.3 Partnerships and Collaborations
- 11.4 Other Developments

12. COMPANY PROFILES

- 12.1 AbbVie Inc

- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 Pfizer Inc
 - 12.2.1 Key Facts
 - 12.2.2 Business Description
 - 12.2.3 Products and Services
 - 12.2.4 Financial Overview
 - 12.2.5 SWOT Analysis
 - 12.2.6 Key Developments
- 12.3 Samsung Biologics Co Ltd
 - 12.3.1 Key Facts
 - 12.3.2 Business Description
 - 12.3.3 Products and Services
 - 12.3.4 Financial Overview
 - 12.3.5 SWOT Analysis
 - 12.3.6 Key Developments
- 12.4 ADMA Biologics, Inc.
 - 12.4.1 Key Facts
 - 12.4.2 Business Description
 - 12.4.3 Products and Services
 - 12.4.4 Financial Overview
 - 12.4.5 SWOT Analysis
 - 12.4.6 Key Developments
- 12.5 WuXi Biologics Inc
 - 12.5.1 Key Facts
 - 12.5.2 Business Description
 - 12.5.3 Products and Services
 - 12.5.4 Financial Overview
 - 12.5.5 SWOT Analysis
 - 12.5.6 Key Developments
- 12.6 Catalent Inc
 - 12.6.1 Key Facts
 - 12.6.2 Business Description
 - 12.6.3 Products and Services
 - 12.6.4 Financial Overview

- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 AGC Biologics AS
 - 12.7.1 Key Facts
 - 12.7.2 Business Description
 - 12.7.3 Products and Services
 - 12.7.4 Financial Overview
 - 12.7.5 SWOT Analysis
 - 12.7.6 Key Developments
- 12.8 AstraZeneca Plc
 - 12.8.1 Key Facts
 - 12.8.2 Business Description
 - 12.8.3 Products and Services
 - 12.8.4 Financial Overview
 - 12.8.5 SWOT Analysis
 - 12.8.6 Key Developments
- 12.9 Amgen Inc
 - 12.9.1 Key Facts
 - 12.9.2 Business Description
 - 12.9.3 Products and Services
 - 12.9.4 Financial Overview
 - 12.9.5 SWOT Analysis
 - 12.9.6 Key Developments
- 12.10 Nitto Avecia
 - 12.10.1 Key Facts
 - 12.10.2 Business Description
 - 12.10.3 Products and Services
 - 12.10.4 Financial Overview
 - 12.10.5 SWOT Analysis
 - 12.10.6 Key Developments
- 12.11 Quality Assistance s.a.
 - 12.11.1 Key Facts
 - 12.11.2 Business Description
 - 12.11.3 Products and Services
 - 12.11.4 Financial Overview
 - 12.11.5 SWOT Analysis
 - 12.11.6 Key Developments

13. APPENDIX

13.1 About Us

List Of Tables

LIST OF TABLES

Table 1. Europe Biologics Market Segmentation

Table 2. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Table 3. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million) - by Product

Table 4. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million) - by Application

Table 5. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million) - by Source

Table 6. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million) - by Manufacturing

Table 7. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million) - by Country

Table 8. Germany: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Product

Table 9. Germany: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 10. Germany: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Source

Table 11. Germany: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Manufacturing

Table 12. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Product

Table 13. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 14. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Source

Table 15. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Manufacturing

Table 16. Italy: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Product

Table 17. Italy: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 18. Italy: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Source

Table 19. Italy: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$

Million) - by Manufacturing

Table 20. France: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Product

Table 21. France: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 22. France: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Source

Table 23. France: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Manufacturing

Table 24. Spain: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Product

Table 25. Spain: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 26. Spain: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Source

Table 27. Spain: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Manufacturing

Table 28. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Product

Table 29. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 30. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Source

Table 31. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Manufacturing

List Of Figures

LIST OF FIGURES

Figure 1. Europe Biologics Market Segmentation - Country

Figure 2. Europe Biologics Market - Key Market Dynamics

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. Europe Biologics Market Revenue (US\$ Million), 2021-2031

Figure 5. Europe Biologics Market Share (%) - by Product (2023 and 2031)

Figure 6. Monoclonal Antibodies: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 7. Vaccine: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 8. Recombinant Hormones/Proteins: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 9. Cell and Gene Therapy: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 10. Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 11. Europe Biologics Market Share (%) - by Application (2023 and 2031)

Figure 12. Cancer: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 13. Infectious Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 14. Autoimmune Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 15. Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 16. Europe Biologics Market Share (%) - by Source (2023 and 2031)

Figure 17. Mammalian: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 18. Microbial: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 19. Europe Biologics Market Share (%) - by Manufacturing (2023 and 2031)

Figure 20. Outsourced: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 21. In-house: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 22. Europe Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)

Figure 23. Germany: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US\$ Million)

Figure 24. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US\$ Million)

Figure 25. Italy: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US\$ Million)

Figure 26. France: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US\$ Million)

Figure 27. Spain: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US\$ Million)

Figure 28. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US\$ Million)

I would like to order

Product name: Europe Biologics Market Forecast to 2031 - Regional Analysis - by Product (Monoclonal Antibodies, Vaccine, Recombinant Hormones/Proteins, Cell and Gene Therapy, and Others), Application (Cancer, Infectious Diseases, Autoimmune Diseases, and Others), Source (Mammalian and Microbial), and Manufacturing (Outsourced and In-house)

Product link: <https://marketpublishers.com/r/E01576F8CC41EN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E01576F8CC41EN.html>